Prelude Therapeutics Inc

Prelude Therapeutics Inc. is a U.S.-based precision oncology biotechnology company focused on discovering and developing novel cancer medicines. The company builds small-molecule drug candidates and other proprietary programs from its research platform and advances selected assets into preclinical and clinical development, often in collaboration with partners.

−847,2 %

−819,6 %

+73,4 %

1.99

1.99

— Prelude Therapeutics Inc
%
Precision oncology drug candidates70% Novel cancer medicines designed to target specific biological drivers in tumors.
Collaborative research and license revenue20% Revenue from collaboration amendments, licenses, and related know-how transfers.
Preclinical discovery programs10% Early-stage proprietary programs and target discovery efforts not yet in trials.

Prelude’s direct customers are primarily pharmaceutical and biotechnology partners that enter collaboration, license,...

  • Biopharmaceutical collaboration partnersprimary

    Partners such as AbCellera and other drug developers that fund or co-develop oncology programs, licenses, or discovery assets.

  • Future oncology prescribers and patientssecondary

    Oncologists and cancer patients who would use approved therapies if candidates successfully reach the market.

  • Clinical research ecosystemsecondary

    CROs, investigative sites, and trial networks that support preclinical and clinical development.

Prelude is headquartered in Wilmington, Delaware and operates as a U.S.-based biotechnology company...

  • •Headquartered in Wilmington, Delaware, United States
  • •Primary research and development operations are U.S.-based
  • •Clinical and regulatory activity is tied to the FDA
  • •Competition for targets and talent is global
  • •Future commercialization would depend on U.S. payor access

Prelude’s strategy is to use its cancer biology and medicinal chemistry platform to identify high-value oncology...

01
Advance lead precision oncology candidatesshort-term

Clinical progress is the main path to value creation in a pre-commercial biotech model.

02
Build and diversify collaboration revenueshort-term

Partnerships can provide non-dilutive capital and external validation of the platform.

03
Expand the discovery platformmedium-term

A broader pipeline increases the chance of finding assets that can reach the clinic or attract partners.

Prelude faces the typical risks of an early-stage oncology biotech: clinical failure, regulatory setbacks, and intense...

critical

Clinical development failure

Drug candidates may not prove safe or effective in trials, which would halt or delay value creation.

Scope
Lead oncology programs and preclinical assets
Materiality
high
critical

Financing and going-concern risk

The company relies on external capital and collaboration proceeds to fund operations before product revenue exists.

Scope
Corporate funding and pipeline continuity
Materiality
high
high

Competitive pressure in precision oncology

Large pharma and biotech peers may develop similar targets faster or with more resources.

Scope
JAK2V617F, KAT6A, SMARCA2 and related oncology programs
Materiality
high
medium

Regulatory and reimbursement uncertainty

Even approved oncology drugs face FDA review risk and later payor coverage pressure.

Scope
Future commercial products in the U.S.
Materiality
medium
ASC 606 collaboration and license revenue
Can create lumpy quarterly revenue from partner agreements
Stock-based compensation valuation
Can materially affect reported R&D and G&A expense
Research and development expense timing
Drives quarter-to-quarter operating loss volatility
Lease and sublease accounting
Can change reported facilities cost and future commitments

OnKure Therapeutics, Inc.

OKUR · Pharmaceutical Preparations

Decoy Therapeutics Inc.

DCOY · Pharmaceutical Preparations

Replimune Group, Inc.

REPL · Biological Products, (No Diagnostic Substances)

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Precipio, Inc.

PRPO · Laboratory Analytical Instruments

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

: 29/04/2026